CTLA4 and infectious disease: The discovery that immunoregulatory molecules such as PD-1 and CTLA-4 are amenable to therapeutic manipulation by antibodies that block these signaling pathways has revolutionized cancer immunotherapy (67–71), and is a potential avenue for novel approaches in the treatment of infectious diseases (29).